We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+3.25%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$350M
AUM Growth
–
Cap. Flow
+$355M
Cap. Flow %
101.24%
Top 10 Hldgs %
67.01%
Holding
24
New
24
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$40.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$32.5M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$24.2M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$23.2M
5
VRDN icon
Viridian Therapeutics
VRDN
+$22.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$38.2M 10.9%
+260,115
New +$40.4M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$29.3M 8.38%
+218,158
New +$32.5M
ZNTL icon
3
Zentalis Pharmaceuticals
ZNTL
$308M
$25.3M 7.21%
+300,434
New +$23.2M
VRDN icon
4
Viridian Therapeutics
VRDN
$2.13B
$23.9M 6.83%
+1,209,051
New +$22.5M
ARNA
5
DELISTED
Arena Pharmaceuticals Inc
ARNA
$23.4M 6.68%
+251,777
New +$16.6M
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
$22.8M 6.52%
+780,480
New +$24.2M
ARVN icon
7
Arvinas
ARVN
$518M
$22.1M 6.3%
+268,519
New +$21.9M
LEGN icon
8
Legend Biotech
LEGN
$4.3B
$18M 5.14%
+385,967
New +$19.6M
IOVA icon
9
Iovance Biotherapeutics
IOVA
$2.23B
$16.1M 4.6%
+844,005
New +$18.6M
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
$15.6M 4.45%
+100,687
New +$16.9M
ARGX icon
11
argenx
ARGX
$57.4B
$14.7M 4.21%
+42,050
New +$12.8M
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.6M 3.89%
+815,581
New +$13.4M
INSM icon
13
Insmed
INSM
$23.2B
$10.7M 3.07%
+394,358
New +$11.3M
SRRA
14
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$10.3M 2.95%
+474,945
New +$10.5M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.84B
$9.92M 2.83%
+453,091
New +$8.37M
LKFT
16
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$9.25M 2.64%
+167,824
New +$8.76M
CCCC icon
17
C4 Therapeutics
CCCC
$376M
$8.33M 2.38%
+258,746
New +$10.2M
KYMR icon
18
Kymera Therapeutics
KYMR
$9.1B
$7.99M 2.28%
+125,858
New +$7.33M
VOR icon
19
Vor Biopharma
VOR
$1.04B
$7.31M 2.09%
+31,467
New +$9.07M
ENTA icon
20
Enanta Pharmaceuticals
ENTA
$372M
$5.65M 1.61%
+75,507
New +$5.93M
OYST
21
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$5.55M 1.59%
+304,238
New +$3.86M
IMCR icon
22
Immunocore
IMCR
$1.78B
$4.6M 1.31%
+134,249
New +$4.86M
ESPR
23
DELISTED
Esperion Therapeutics
ESPR
$4.2M 1.2%
+839,257
New +$6.72M
GRCL
24
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.29M 0.94%
+545,388
New +$5.24M

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2021 Portfolio in Review

Q4 2021 is the first quarter with a 13F filing on record for Paradigm Biocapital Advisors, which disclosed 24 positions worth $350M. Its ten largest holdings account for 67% of the portfolio.

Its largest position is Mirati Therapeutics, Inc. Common Stock: 260,115 shares worth $38.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Paradigm Biocapital Advisors's largest Q4 2021 buy was Mirati Therapeutics, Inc. Common Stock: 260,115 shares worth $38.2M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 67% of its $350M portfolio in Q4 2021.
  • Paradigm Biocapital Advisors disclosed 24 positions in Q4 2021, its first 13F filing on record.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.